0
0
0
0
1
2
3
$0
Is Merck solid or fragile? The Finex Financial Health Scanner reads MRK's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $65.0B |
|---|---|
| Net income | $18.3B |
| Operating margin | 32.6% |
| Net margin | 28.1% |
| Cash and investments | $14.6B |
| Total debt | $49.3B |
| Free cash flow | $14.0B |
| Revenue growth (1 year) | 1.3% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.